David A Hormuth, Angela M Jarrett, Guillermo Lorenzo, Ernesto A B F Lima, Chengyue Wu, Caroline Chung, Debra Patt, Thomas E Yankeelov
{"title":"Math, magnets, and medicine: enabling personalized oncology.","authors":"David A Hormuth, Angela M Jarrett, Guillermo Lorenzo, Ernesto A B F Lima, Chengyue Wu, Caroline Chung, Debra Patt, Thomas E Yankeelov","doi":"10.1080/23808993.2021.1878023","DOIUrl":null,"url":null,"abstract":"Oden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX, USA; Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX, USA; Department of Civil Engineering and Architecture, University of Pavia, Pavia, Italy; Texas Advanced Computing Center, The University of Texas at Austin, Austin, TX, USA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Texas Oncology, Austin, TX, USA; Departments of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA; Department of Diagnostic Medicine, The University of Texas at Austin, Austin, TX, USA; Department of Oncology, The University of Texas at Austin, Austin, TX, USA; Departments of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2021.1878023","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2021.1878023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 12
Abstract
Oden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX, USA; Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX, USA; Department of Civil Engineering and Architecture, University of Pavia, Pavia, Italy; Texas Advanced Computing Center, The University of Texas at Austin, Austin, TX, USA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Texas Oncology, Austin, TX, USA; Departments of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA; Department of Diagnostic Medicine, The University of Texas at Austin, Austin, TX, USA; Department of Oncology, The University of Texas at Austin, Austin, TX, USA; Departments of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
期刊介绍:
Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.